ContraFect Corporation Concludes Phase 1 Study of CF-301

ContraFect Corporation (CFRX) (CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced the Phase 1, first-in-human study of CF-301 has concluded. As specified in the protocol, the independent data safety monitoring board (DSMB) reviewed safety, tolerability, and pharmacokinetic data from healthy volunteers dosed in all of the planned cohorts. The DSMB observed no clinical adverse safety signals associated with CF-301 in the study.

This entry was posted in Recent Development News: Q4 - 2015, Recent Developments. Bookmark the permalink.
Read Full Article »